Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART
Article Sidebar
Main Article Content
Abstract
Background: Combined antiretroviral treatment (cART) for HIV infection is highly effective in controlling viral replication. However, it cannot achieve a sterilizing cure. Several strategies have been proposed to achieve a functional cure, some of them based on immune-mediated clearing of persistently infected cells. Here, we aimed at identifying factors related to CD8TC and CD4TC quality before cART initiation that associate with the persistence of CD8TC antiviral response after cART, inflammation levels, and the size of the viral reservoir.
Methods: Samples from 25 persons living with HIV were obtained before and after (15 months) cART initiation. Phenotype and functionality of bulk and HIV-specific T cells were assayed by flow cytometry ex vivo or after expansion in pre-cART or post-cART samples, respectively. Cell-Associated (CA) HIV DNA (total and integrated) and RNA (unspliced [US] and multiple spliced [MS]) were quantitated by real-time PCR on post-cART samples. Post-cART plasma levels of CXCL10 (IP-10), soluble CD14 (sCD14) and soluble CD163 (sCD163) were measured by ELISA.
Results: Pre-cART phenotype of CD8TCs and magnitude and phenotype of HIV-specific response correlated with the phenotype and functionality of CD8TCs post-cART. Moreover, the phenotype of the CD8TCs pre-cART correlated with markers of HIV persistence and inflammation post-cART. Finally, exhaustion and differentiation of CD4TCs pre-cART were associated with the composition of the HIV reservoir post-cART and the level of inflammation.
Conclusions: Overall, this work provides data to help understand and identify parameters that could be used as markers in the development of immune-based functional HIV cure strategies.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258-71. Epub 2014/06/09. doi: 10.1016/S0140-6736(14)60164-1. PubMed PMID: 24907868.
Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019;321(5):451-2. Epub 2019/01/11. doi: 10.1001/jama.2018.21167. PubMed PMID: 30629090.
Hull M, Lange J, Montaner JS. Treatment as prevention--where next? Curr HIV/AIDS Rep. 2014;11(4):496-504. Epub 2014/11/12. doi: 10.1007/s11904-014-0237-5. PubMed PMID: 25384357; PMCID: PMC4268430.
Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381(9883):2109-17. Epub 2013/04/02. doi: 10.1016/S0140-6736(13)60104-X. PubMed PMID: 23541541; PMCID: PMC3815451.
Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS. 2011;25(7):885-97. Epub 2011/03/23. doi: 10.1097/QAD.0b013e3283467041. PubMed PMID: 21422987.
Davey RT, Jr., Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, Lane HC. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999;96(26):15109-14. Epub 1999/12/28. doi: 10.1073/pnas.96.26.15109. PubMed PMID: 10611346; PMCID: PMC24781.
Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633-45. Epub 2013/10/22. doi: 10.1016/j.immuni.2013.10.001. PubMed PMID: 24138880; PMCID: PMC4012895.
Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses. 2019;11(3). Epub 2019/03/02. doi: 10.3390/v11030200. PubMed PMID: 30818749; PMCID: PMC6466530.
Gupta RK, Peppa D, Hill AL, Galvez C, Salgado M, Pace M, McCoy LE, Griffith SA, Thornhill J, Alrubayyi A, Huyveneers LEP, Nastouli E, Grant P, Edwards SG, Innes AJ, Frater J, Nijhuis M, Wensing AMJ, Martinez-Picado J, Olavarria E. Evidence for HIV-1 cure after CCR5Delta32/Delta32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV. 2020;7(5):e340-e7. Epub 2020/03/15. doi: 10.1016/S2352-3018(20)30069-2. PubMed PMID: 32169158; PMCID: PMC7606918.
Yang OO, Cumberland WG, Escobar R, Liao D, Chew KW. Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. AIDS. 2017;31(8):1091-8. Epub 2017/03/17. doi: 10.1097/QAD.0000000000001443. PubMed PMID: 28301422; PMCID: PMC5657480.
Jiang C, Lian X, Gao C, Sun X, Einkauf KB, Chevalier JM, Chen SMY, Hua S, Rhee B, Chang K, Blackmer JE, Osborn M, Peluso MJ, Hoh R, Somsouk M, Milush J, Bertagnolli LN, Sweet SE, Varriale JA, Burbelo PD, Chun TW, Laird GM, Serrao E, Engelman AN, Carrington M, Siliciano RF, Siliciano JM, Deeks SG, Walker BD, Lichterfeld M, Yu XG. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature. 2020;585(7824):261-7. Epub 2020/08/28. doi: 10.1038/s41586-020-2651-8. PubMed PMID: 32848246; PMCID: PMC7837306.
Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C, Group AVS. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211. Epub 2013/03/22. doi: 10.1371/journal.ppat.1003211. PubMed PMID: 23516360; PMCID: PMC3597518.
Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692-8. Epub 2009/02/14. doi: 10.1056/NEJMoa0802905. PubMed PMID: 19213682.
Pitman MC, Lau JSY, McMahon JH, Lewin SR. Barriers and strategies to achieve a cure for HIV. Lancet HIV. 2018;5(6):e317-e28. Epub 2018/06/13. doi: 10.1016/S2352-3018(18)30039-0. PubMed PMID: 29893245; PMCID: PMC6559798.
Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, International ASTaCWG, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen EA, Corbelli GM, Eholie S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22(8):839-50. Epub 2016/07/12. doi: 10.1038/nm.4108. PubMed PMID: 27400264; PMCID: PMC5322797.
Collins DR, Gaiha GD, Walker BD. CD8(+) T cells in HIV control, cure and prevention. Nat Rev Immunol. 2020;20(8):471-82. Epub 2020/02/14. doi: 10.1038/s41577-020-0274-9. PubMed PMID: 32051540; PMCID: PMC7222980.
Turk G, Ghiglione Y, Falivene J, Socias ME, Laufer N, Coloccini RS, Rodriguez AM, Ruiz MJ, Pando MA, Giavedoni LD, Cahn P, Sued O, Salomon H, Gherardi MM. Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartment. J Virol. 2013;87(13):7445-62. Epub 2013/04/26. doi: 10.1128/JVI.00865-13. PubMed PMID: 23616666; PMCID: PMC3700299.
Ghiglione Y, Falivene J, Ruiz MJ, Laufer N, Socias ME, Cahn P, Giavedoni L, Sued O, Gherardi MM, Salomon H, Turk G. Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression. PLoS One. 2014;9(8):e104235. Epub 2014/08/06. doi: 10.1371/journal.pone.0104235. PubMed PMID: 25093660; PMCID: PMC4122399.
Falivene J, Ghiglione Y, Laufer N, Socias ME, Holgado MP, Ruiz MJ, Maeto C, Figueroa MI, Giavedoni LD, Cahn P, Salomon H, Sued O, Turk G, Gherardi MM. Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8(+) T-cell responses and disease progression. Sci Rep. 2015;5:11511. Epub 2015/06/24. doi: 10.1038/srep11511. PubMed PMID: 26099972; PMCID: PMC4477236.
Ghiglione Y, Trifone C, Salido J, Rhodes A, Ruiz MJ, Polo ML, Salomon H, Laufer N, Sued O, Lewin SR, Turk G. PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence. J Acquir Immune Defic Syndr. 2019;80(1):1-6. Epub 2018/11/07. doi: 10.1097/QAI.0000000000001887. PubMed PMID: 30399040.
Salido J, Ruiz MJ, Trifone C, Figueroa MI, Caruso MP, Gherardi MM, Sued O, Salomon H, Laufer N, Ghiglione Y, Turk G. Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8(+) T-Cells From HIV(+) Subjects Who Initiated cART at Different Time-Points After Acute Infection. Front Immunol. 2018;9:2443. Epub 2018/11/09. doi: 10.3389/fimmu.2018.02443. PubMed PMID: 30405632; PMCID: PMC6205955.
Socias ME, Sued O, Laufer N, Lazaro ME, Mingrone H, Pryluka D, Remondegui C, Figueroa MI, Cesar C, Gun A, Turk G, Bouzas MB, Kavasery R, Krolewiecki A, Perez H, Salomon H, Cahn P, Grupo Argentino de Seroconversion Study G. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc. 2011;14:40. Epub 2011/08/13. doi: 10.1186/1758-2652-14-40. PubMed PMID: 21831310; PMCID: PMC3179691.
Malhotra U, Li F, Nolin J, Allison M, Zhao H, Mullins JI, Self S, McElrath MJ. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol. 2007;81(10):5225-37. Epub 2007/03/03. doi: 10.1128/JVI.02564-06. PubMed PMID: 17329342; PMCID: PMC1900243.
Saez-Cirion A, Shin SY, Versmisse P, Barre-Sinoussi F, Pancino G. Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat Protoc. 2010;5(6):1033-41. Epub 2010/06/12. doi: 10.1038/nprot.2010.73. PubMed PMID: 20539279.
Hermans IF, Silk JD, Yang J, Palmowski MJ, Gileadi U, McCarthy C, Salio M, Ronchese F, Cerundolo V. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods. 2004;285(1):25-40. Epub 2004/02/12. doi: 10.1016/j.jim.2003.10.017. PubMed PMID: 14871532.
Pasternak AO, Berkhout B. What do we measure when we measure cell-associated HIV RNA. Retrovirology. 2018;15(1):13. Epub 2018/01/31. doi: 10.1186/s12977-018-0397-2. PubMed PMID: 29378657; PMCID: PMC5789533.
Vandergeeten C, Fromentin R, Merlini E, Lawani MB, DaFonseca S, Bakeman W, McNulty A, Ramgopal M, Michael N, Kim JH, Ananworanich J, Chomont N. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol. 2014;88(21):12385-96. Epub 2014/08/15. doi: 10.1128/JVI.00609-14. PubMed PMID: 25122785; PMCID: PMC4248919.
Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, Cornelissen M, Lukashov VV. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol. 2008;46(7):2206-11. Epub 2008/05/09. doi: 10.1128/JCM.00055-08. PubMed PMID: 18463204; PMCID: PMC2446885.
Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol. 2014;88(17):10056-65. Epub 2014/06/27. doi: 10.1128/JVI.01046-14. PubMed PMID: 24965451; PMCID: PMC4136362.
Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, Rosenberg ES, Williams KC, Grinspoon S. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204(8):1227-36. Epub 2011/09/16. doi: 10.1093/infdis/jir520. PubMed PMID: 21917896; PMCID: PMC3203384.
Williams JC, Zhang X, Karki M, Chi YY, Wallet SM, Rudy BJ, Nichols SL, Goodenow MM, Sleasman JW. Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls. J Leukoc Biol. 2018;103(4):671-80. Epub 2018/01/30. doi: 10.1002/JLB.3A0717-294RR. PubMed PMID: 29377283; PMCID: PMC6528780.
Novelli S, Lecuroux C, Goujard C, Reynes J, Villemant A, Blum L, Essat A, Avettand-Fenoel V, Launay O, Molina JM, Bourgeois C, Meyer L. Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection. EBioMedicine. 2020;62:103129. Epub 2020/11/29. doi: 10.1016/j.ebiom.2020.103129. PubMed PMID: 33248370; PMCID: PMC7704414.
Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC, Group ISS. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780-90. Epub 2011/01/22. doi: 10.1093/infdis/jiq118. PubMed PMID: 21252259; PMCID: PMC3071127.
Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis. 2011;204(1):154-63. Epub 2011/06/02. doi: 10.1093/infdis/jir214. PubMed PMID: 21628670; PMCID: PMC3105035.
Noel N, Boufassa F, Lecuroux C, Saez-Cirion A, Bourgeois C, Dunyach-Remy C, Goujard C, Rouzioux C, Meyer L, Pancino G, Venet A, Lambotte O, Group ACCS. Elevated IP10 levels are associated with immune activation and low CD4(+) T-cell counts in HIV controller patients. AIDS. 2014;28(4):467-76. Epub 2014/01/01. doi: 10.1097/QAD.0000000000000174. PubMed PMID: 24378753.
Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, Martinez-Maza O, Bream JH. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463-71. Epub 2015/01/30. doi: 10.1097/QAD.0000000000000545. PubMed PMID: 25630041; PMCID: PMC4311407.
Castillo-Mancilla JR, Brown TT, Palella FJ, Jr., Macatangay BJC, Breen EC, Jacobson LP, Wada NI. Partial Normalization of Biomarkers of Inflammation and Immune Activation Among Virally Suppressed Men With HIV Infection and High ART Adherence. Open Forum Infect Dis. 2020;7(4):ofaa099. Epub 2020/04/24. doi: 10.1093/ofid/ofaa099. PubMed PMID: 32322603; PMCID: PMC7162619.
Liovat AS, Rey-Cuille MA, Lecuroux C, Jacquelin B, Girault I, Petitjean G, Zitoun Y, Venet A, Barre-Sinoussi F, Lebon P, Meyer L, Sinet M, Muller-Trutwin M. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One. 2012;7(10):e46143. Epub 2012/10/12. doi: 10.1371/journal.pone.0046143. PubMed PMID: 23056251; PMCID: PMC3462744.
Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol. 2012;40(2):560-6. Epub 2011/11/01. doi: 10.3892/ijo.2011.1247. PubMed PMID: 22038159.
Gomez-Rial J, Curras-Tuala MJ, Rivero-Calle I, Gomez-Carballa A, Cebey-Lopez M, Rodriguez-Tenreiro C, Dacosta-Urbieta A, Rivero-Velasco C, Rodriguez-Nunez N, Trastoy-Pena R, Rodriguez-Garcia J, Salas A, Martinon-Torres F. Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology. Front Immunol. 2020;11:560381. Epub 2020/10/20. doi: 10.3389/fimmu.2020.560381. PubMed PMID: 33072099; PMCID: PMC7538662.
Gotsch F, Romero R, Friel L, Kusanovic JP, Espinoza J, Erez O, Than NG, Mittal P, Edwin S, Yoon BH, Kim CJ, Mazaki-Tovi S, Chaiworapongsa T, Hassan SS. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med. 2007;20(11):777-92. Epub 2007/10/19. doi: 10.1080/14767050701483298. PubMed PMID: 17943641; PMCID: PMC2396489.
Perdomo-Celis F, Taborda NA, Rugeles MT. CD8(+) T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy. Front Immunol. 2019;10:1896. Epub 2019/08/27. doi: 10.3389/fimmu.2019.01896. PubMed PMID: 31447862; PMCID: PMC6697065.
Warren JA, Clutton G, Goonetilleke N. Harnessing CD8(+) T Cells Under HIV Antiretroviral Therapy. Front Immunol. 2019;10:291. Epub 2019/03/14. doi: 10.3389/fimmu.2019.00291. PubMed PMID: 30863403; PMCID: PMC6400228.
Jones RB, Walker BD. HIV-specific CD8(+) T cells and HIV eradication. J Clin Invest. 2016;126(2):455-63. Epub 2016/01/06. doi: 10.1172/JCI80566. PubMed PMID: 26731469; PMCID: PMC4731167.
McDermott AB, Koup RA. CD8(+) T cells in preventing HIV infection and disease. AIDS. 2012;26(10):1281-92. Epub 2012/03/24. doi: 10.1097/QAD.0b013e328353bcaf. PubMed PMID: 22441256.
Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, Deeks SG, McCune JM. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One. 2014;9(1):e85613. Epub 2014/01/28. doi: 10.1371/journal.pone.0085613. PubMed PMID: 24465619; PMCID: PMC3897457.
Lam S, Sung J, Cruz C, Castillo-Caro P, Ngo M, Garrido C, Kuruc J, Archin N, Rooney C, Margolis D, Bollard C. Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. Mol Ther. 2015;23(2):387-95. Epub 2014/11/05. doi: 10.1038/mt.2014.207. PubMed PMID: 25366030; PMCID: PMC4445615.
Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, Huber M, Karrer U, Oxenius A. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol. 2008;82(7):3391-404. Epub 2008/01/18. doi: 10.1128/JVI.02383-07. PubMed PMID: 18199637; PMCID: PMC2268491.
Weekes MP, Wills MR, Sissons JG, Carmichael AJ. Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy. Immunology. 2006;118(1):25-38. Epub 2006/04/25. doi: 10.1111/j.1365-2567.2006.02334.x. PubMed PMID: 16630020; PMCID: PMC1782266.
Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT, Jr., Connors M. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol. 2009;83(22):11876-89. Epub 2009/09/04. doi: 10.1128/JVI.01153-09. PubMed PMID: 19726501; PMCID: PMC2772718.
Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Hurley A, Markowitz M, Ho DD, McMichael AJ, Nixon DF. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999;73(1):797-800. Epub 1998/12/16. doi: 10.1128/JVI.73.1.797-800.1999. PubMed PMID: 9847391; PMCID: PMC103892.
Conrad JA, Ramalingam RK, Duncan CB, Smith RM, Wei J, Barnett L, Simons BC, Lorey SL, Kalams SA. Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance. J Virol. 2012;86(8):4213-21. Epub 2012/01/20. doi: 10.1128/JVI.06000-11. PubMed PMID: 22258246; PMCID: PMC3318638.
Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol. 2001;75(14):6508-16. Epub 2001/06/20. doi: 10.1128/JVI.75.14.6508-6516.2001. PubMed PMID: 11413318; PMCID: PMC114374.
Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol. 1999;73(8):6721-8. Epub 1999/07/10. doi: 10.1128/JVI.73.8.6721-6728.1999. PubMed PMID: 10400770; PMCID: PMC112757.
Mahnke YD, Song K, Sauer MM, Nason MC, Giret MT, Carvalho KI, Costa PR, Roederer M, Kallas EG. Early immunologic and virologic predictors of clinical HIV-1 disease progression. AIDS. 2013;27(5):697-706. Epub 2012/12/06. doi: 10.1097/QAD.0b013e32835ce2e9. PubMed PMID: 23211771.
Burgers WA, Riou C, Mlotshwa M, Maenetje P, de Assis Rosa D, Brenchley J, Mlisana K, Douek DC, Koup R, Roederer M, de Bruyn G, Karim SA, Williamson C, Gray CM, Team CAIS. Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol. 2009;182(8):4751-61. Epub 2009/04/04. doi: 10.4049/jimmunol.0803801. PubMed PMID: 19342652; PMCID: PMC2792921.
Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410(6824):106-11. Epub 2001/03/10. doi: 10.1038/35065118. PubMed PMID: 11242051.
Yue FY, Cohen JC, Ho M, Rahman A, Liu J, Mujib S, Saiyed A, Hundal S, Khozin A, Bonner P, Liu D, Benko E, Kovacs C, Ostrowski M. HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection. J Virol. 2017;91(8). Epub 2017/02/10. doi: 10.1128/JVI.02233-16. PubMed PMID: 28179527; PMCID: PMC5375660.
Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, Simmens S, Walker BD, Mellors JW, Jones RB. T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS Pathog. 2017;13(9):e1006629. Epub 2017/09/21. doi: 10.1371/journal.ppat.1006629. PubMed PMID: 28931091; PMCID: PMC5624641.
Takata H, Buranapraditkun S, Kessing C, Fletcher JL, Muir R, Tardif V, Cartwright P, Vandergeeten C, Bakeman W, Nichols CN, Pinyakorn S, Hansasuta P, Kroon E, Chalermchai T, O'Connell R, Kim J, Phanuphak N, Robb ML, Michael NL, Chomont N, Haddad EK, Ananworanich J, Trautmann L, Rv254/Search, the RVSSG. Delayed differentiation of potent effector CD8(+) T cells reducing viremia and reservoir seeding in acute HIV infection. Sci Transl Med. 2017;9(377). Epub 2017/02/17. doi: 10.1126/scitranslmed.aag1809. PubMed PMID: 28202771; PMCID: PMC5678930.
Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, Lawson BO, Nega M, Easley K, Schmitz JE, Bosinger SE, Paiardini M, Chahroudi A, Vanderford TH, Estes JD, Lifson JD, Derdeyn CA, Silvestri G. CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. Immunity. 2016;45(3):656-68. Epub 2016/09/23. doi: 10.1016/j.immuni.2016.08.018. PubMed PMID: 27653601; PMCID: PMC5087330.
Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe. 2017;21(4):494-506 e4. Epub 2017/04/14. doi: 10.1016/j.chom.2017.03.008. PubMed PMID: 28407485; PMCID: PMC5433942.
Imamichi H, Smith M, Adelsberger JW, Izumi T, Scrimieri F, Sherman BT, Rehm CA, Imamichi T, Pau A, Catalfamo M, Fauci AS, Lane HC. Defective HIV-1 proviruses produce viral proteins. Proc Natl Acad Sci U S A. 2020;117(7):3704-10. Epub 2020/02/08. doi: 10.1073/pnas.1917876117. PubMed PMID: 32029589; PMCID: PMC7035625.
Stevenson EM, Ward AR, Truong R, Thomas AS, Huang SH, Dilling TR, Terry S, Bui JK, Mota TM, Danesh A, Lee GQ, Gramatica A, Khadka P, Alberto WDC, Gandhi RT, McMahon DK, Lalama CM, Bosch RJ, Macatangay B, Cyktor JC, Eron JJ, Mellors JW, Jones RB, Team ACTGA. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight. 2021;6(3). Epub 2021/01/06. doi: 10.1172/jci.insight.142640. PubMed PMID: 33400687; PMCID: PMC7934865.
Fromentin R, Chomont N. HIV persistence in subsets of CD4+ T cells: 50 shades of reservoirs. Semin Immunol. 2020:101438. Epub 2020/12/05. doi: 10.1016/j.smim.2020.101438. PubMed PMID: 33272901.
Soriano-Sarabia N, Bateson RE, Dahl NP, Crooks AM, Kuruc JD, Margolis DM, Archin NM. Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J Virol. 2014;88(24):14070-7. Epub 2014/09/26. doi: 10.1128/JVI.01900-14. PubMed PMID: 25253353; PMCID: PMC4249150.
Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893-900. Epub 2009/06/23. doi: 10.1038/nm.1972. PubMed PMID: 19543283; PMCID: PMC2859814.
Wonderlich ER, Subramanian K, Cox B, Wiegand A, Lackman-Smith C, Bale MJ, Stone M, Hoh R, Kearney MF, Maldarelli F, Deeks SG, Busch MP, Ptak RG, Kulpa DA. Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals. PLoS Pathog. 2019;15(10):e1008074. Epub 2019/10/15. doi: 10.1371/journal.ppat.1008074. PubMed PMID: 31609991; PMCID: PMC6812841.
Pardons M, Baxter AE, Massanella M, Pagliuzza A, Fromentin R, Dufour C, Leyre L, Routy JP, Kaufmann DE, Chomont N. Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. PLoS Pathog. 2019;15(2):e1007619. Epub 2019/02/28. doi: 10.1371/journal.ppat.1007619. PubMed PMID: 30811499; PMCID: PMC6411230.
Grau-Exposito J, Serra-Peinado C, Miguel L, Navarro J, Curran A, Burgos J, Ocana I, Ribera E, Torrella A, Planas B, Badia R, Castellvi J, Falco V, Crespo M, Buzon MJ. A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4(+) T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. mBio. 2017;8(4). Epub 2017/07/13. doi: 10.1128/mBio.00876-17. PubMed PMID: 28698276; PMCID: PMC5513707.
Hiener B, Horsburgh BA, Eden JS, Barton K, Schlub TE, Lee E, von Stockenstrom S, Odevall L, Milush JM, Liegler T, Sinclair E, Hoh R, Boritz EA, Douek D, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S. Identification of Genetically Intact HIV-1 Proviruses in Specific CD4(+) T Cells from Effectively Treated Participants. Cell Rep. 2017;21(3):813-22. Epub 2017/10/19. doi: 10.1016/j.celrep.2017.09.081. PubMed PMID: 29045846; PMCID: PMC5960642.
Kulpa DA, Talla A, Brehm JH, Ribeiro SP, Yuan S, Bebin-Blackwell AG, Miller M, Barnard R, Deeks SG, Hazuda D, Chomont N, Sekaly RP. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4(+) T Cells. J Virol. 2019;93(24). Epub 2019/10/04. doi: 10.1128/JVI.00969-19. PubMed PMID: 31578289; PMCID: PMC6880164.
Eller MA, Hong T, Creegan M, Nau ME, Sanders-Buell E, Slike BM, Krebs SJ, Ratto-Kim S, McElrath MJ, Katabira ET, Bolton DL, Michael NL, Robb ML, Tovanabutra S, Baeten JM, Sandberg JK. Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. AIDS. 2020;34(2):197-202. Epub 2019/11/26. doi: 10.1097/QAD.0000000000002432. PubMed PMID: 31764072.
McGary CS, Deleage C, Harper J, Micci L, Ribeiro SP, Paganini S, Kuri-Cervantes L, Benne C, Ryan ES, Balderas R, Jean S, Easley K, Marconi V, Silvestri G, Estes JD, Sekaly RP, Paiardini M. CTLA-4(+)PD-1(-) Memory CD4(+) T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques. Immunity. 2017;47(4):776-88 e5. Epub 2017/10/19. doi: 10.1016/j.immuni.2017.09.018. PubMed PMID: 29045906; PMCID: PMC5679306.
Evans VA, van der Sluis RM, Solomon A, Dantanarayana A, McNeil C, Garsia R, Palmer S, Fromentin R, Chomont N, Sekaly RP, Cameron PU, Lewin SR. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS. 2018;32(11):1491-7. Epub 2018/05/11. doi: 10.1097/QAD.0000000000001849. PubMed PMID: 29746296; PMCID: PMC6026054.
Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, Killian M, Epling L, Hoh R, Sinclair E, Hecht FM, Bacchetti P, Deeks SG, Lewin SR, Sekaly RP, Chomont N. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathog. 2016;12(7):e1005761. Epub 2016/07/16. doi: 10.1371/journal.ppat.1005761. PubMed PMID: 27415008; PMCID: PMC4944956.
Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sekaly RP, Chomont N. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals. Nat Commun. 2019;10(1):814. Epub 2019/02/20. doi: 10.1038/s41467-019-08798-7. PubMed PMID: 30778080; PMCID: PMC6379401.
Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, Chomont N, Bar KJ, Yu XG, Lichterfeld M, Alcami J, Hazuda D, Bushman F, Siliciano JD, Betts MR, Spivak AM, Planelles V, Hahn BH, Smith DM, Ho YC, Buzon MJ, Gaebler C, Paiardini M, Li Q, Estes JD, Hope TJ, Kostman J, Mounzer K, Caskey M, Fox L, Frank I, Riley JL, Tebas P, Montaner LJ, infection B-HDCtCH-. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med. 2020;26(9):1339-50. Epub 2020/09/09. doi: 10.1038/s41591-020-1022-1. PubMed PMID: 32895573; PMCID: PMC7703694.